Adagene Announces Poster Presentations of Clinical Data for Two Novel Antibody Programs at ESMO Immuno-Oncology Congress 2021

Rhea-AI Summary

Adagene Inc. (Nasdaq: ADAG) announced two poster presentations at the ESMO-IO Congress 2021 showcasing clinical data for its anti-CD137 agonist, ADG106, and anti-CTLA-4 monoclonal antibody, ADG116. The data highlight the potential of the NEObody™ technology in improving T-cell activation and safety profiles in cancer immunotherapy. Key presentations include biomarker kinetics for ADG106 and a dose-finding study for ADG116. The conference takes place from December 8-11, 2021, with details available after December 2.

Positive

• Showcased promising clinical data for ADG106 and ADG116 at ESMO-IO 2021.
• Supported by NEObody™ technology, enhancing T-cell activation and safety in trials.

Negative

• No specific clinical results or efficacy data provided for drug candidates in the PR.
• Forward-looking statements include risks related to regulatory approvals and clinical developments.

SAN DIEGO and SUZHOU, China, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based immunotherapies, today announced two poster presentations featuring clinical data for its anti-CD137 agonist, ADG106, and anti-CTLA-4 monoclonal antibody, ADG116, at the European Society for Medical Oncology Immuno-Oncology Congress (ESMO-IO) 2021.

The conference abstracts are expected to be published on the ESMO-IO website on Thursday, December 2, 2021 and posters available on Monday, December 6 in advance of the hybrid meeting being held virtually and in Geneva, Switzerland from December 8 to 11, 2021.

“These clinical data from two of our ongoing NEObody™ clinical programs showcase the importance of our pioneering approach to target a unique epitope and reflect the dynamic interactivity between an antibody and antigen,” said Peter Luo, Ph.D., Co-founder, Chief Executive Officer and Chairman of Adagene. “The pharmacodynamic biomarker findings from our ongoing ADG106 trial with the anti-PD-1 toripalimab reinforce the potential synergistic combination for strong T-cell activation. For our novel anti-CTLA-4 program, data from the ongoing dose escalation of ADG116 monotherapy support the robust safety profile and dose dependent T-cell activation in both hot and cold tumors, suggesting potential clinical benefit following our translational studies. Each of these analyses highlights the promise of our tailor-made programs to achieve the fine balance between safety and efficacy – thereby unlocking the full value of some of the most promising yet challenging immuno-oncology targets today.”

Details for the poster presentations during ESMO-IO 2021 include:

• Title: Assessment of Biomarker Kinetics for ADG106 (anti-CD137 agonist) as monotherapy or combined with toripalimab
  Presentation Number: 43P
  Date: Monday, December 6, 2021
  Time: 12:00 Central European Time

• Title: Phase 1 dose-finding study of a novel anti–CTLA-4 antibody ADG116 as monotherapy in patients with advanced solid tumors
  Presentation Number: 137P
  Date: Monday, December 6, 2021
  Time: 12:00 Central European Time

Both the ADG106 and ADG116 programs use Adagene’s innovative NEObody technology, which enables targeting of unique and highly conserved epitopes against a broad range of antigens. These species cross-reactive antibodies not only have the potential to reveal new biological functions of the targets, but also facilitate preclinical studies using various immune intact animal models, resulting in high fidelity translation from preclinical to clinical studies. The company is also developing an anti-CTLA-4 antibody, ADG126, using its SAFEbody® precision masking technology.

About Adagene
Adagene Inc. (Nasdaq: ADAG) is a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. Adagene combines computational biology and artificial intelligence to design novel antibodies that address unmet patient needs. Powered by its proprietary Dynamic Precision Library (DPL) platform, composed of NEObody™, SAFEbody®, and POWERbody™ technologies, Adagene’s highly differentiated pipeline features novel immunotherapy programs. Adagene has forged strategic collaborations with reputable global partners that leverage its technology in multiple approaches at the vanguard of science.

For more information, please visit: https://investor.adagene.com.

Safe Harbor Statement

This press release contains forward-looking statements, including statements regarding the potential implications of clinical data for patients, and Adagene’s advancement of, and anticipated clinical activities, clinical development, regulatory milestones, and commercialization of its product candidates. Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including but not limited to Adagene’s ability to demonstrate the safety and efficacy of its drug candidates; the clinical results for its drug candidates, which may not support further development or regulatory approval; the content and timing of decisions made by the relevant regulatory authorities regarding regulatory approval of Adagene’s drug candidates; Adagene’s ability to achieve commercial success for its drug candidates, if approved; Adagene’s ability to obtain and maintain protection of intellectual property for its technology and drugs; Adagene’s reliance on third parties to conduct drug development, manufacturing and other services; Adagene’s limited operating history and Adagene’s ability to obtain additional funding for operations and to complete the development and commercialization of its drug candidates; Adagene’s ability to enter into additional collaboration agreements beyond its existing strategic partnerships or collaborations, and the impact of the COVID-19 pandemic on Adagene’s clinical development, commercial and other operations, as well as those risks more fully discussed in the “Risk Factors” section in Adagene’s filings with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to Adagene, and Adagene undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law.

Internal Contact:
Ami Knoefler
Adagene
650-739-9952
ir@adagene.com

External Contact:
Bruce Mackle
LifeSci Advisors
646-889-1200
bmackle@lifesciadvisors.com

FAQ

What clinical data was presented for ADG106 at ESMO-IO 2021?

ADG106's biomarker kinetics were highlighted as part of its potential as a monotherapy or in combination with toripalimab.

What is the focus of the ADG116 program?

ADG116 is in a Phase 1 dose-finding study aimed at evaluating its safety and effectiveness in patients with advanced solid tumors.

When were the poster presentations scheduled during the ESMO-IO Congress?

Both poster presentations are scheduled for December 6, 2021, at 12:00 Central European Time.

What is NEObody technology used for in Adagene's programs?

NEObody technology is designed to target unique epitopes to improve the efficacy and safety of antibody-based therapies.

What are the potential risks mentioned for Adagene's drug candidates?

Risks include the ability to demonstrate safety and efficacy, regulatory approval challenges, and reliance on third parties for drug development.